Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
194
resultados
Última actualización
05/08/2025 [06:55:00]
Resultados 25 a 50 de 194
Resumen de: CN120394850A
本发明涉及一种基于可电离金纳米粒子的mRNA脂质体。所述可电离的金纳米粒子由金纳米粒子和可电离脂质组成，所述可电离脂质同金纳米粒子表面的金原子形成配体结构，由此在金颗粒表面形成了可电离脂质层。由于可电离金纳米粒子与带有负电的mRNA结合形成复合物，降低了后续脂质体胶束包覆的能量，从而促进了脂质体组装，提供了包封效率。本发明脂质体在活体层面具有更好的递送效果，而且与其包封率的提高存在相关性。
Resumen de: TW202428878A
Methods and compositions for genetically modifying a cell are provided.
Resumen de: CN120392644A
本发明涉及纳米治疗领域，尤其涉及改善线粒体膜透通性延缓衰老促进骨修复的超声刺激转换治疗平台。本发明提供了水凝胶微球，包括：PDA包裹的金纳米棒和GelMA水凝胶；所述金纳米棒负载于所述GelMA水凝胶。本发明在热刺激逆转衰老干细胞治疗衰老骨缺损潜力的基础上，设计了基于物理信号转换策略的治疗系统，并进一步结合多组学分析解析热刺激疗法的潜在通路和靶点，更为治疗衰老骨缺损新技术的创新发展和应用转化搭建了全新的研究平台。
Resumen de: CN120392697A
本发明属于医药领域，具体公开核壳防护型智能脂质递送系统及其制备方法与应用。其结构为：Y型DNA支架通过双链DNA即dsDNA交联形成致密网状DNA外壳，并与胆固醇胶束表面的DNA杂交进一步锚定在胆固醇胶束表面形成稳定的核壳结构，通过核酸适配体在外壳表面修饰构建的靶向型核壳系统。本发明的创新设计通过时空可控的药物释放、自反馈的荧光监测、以及级联放大的药物释放机制，实现了化疗‑基因治疗的协同增效，为抗肿瘤联合治疗提供了新型纳米技术平台。
Resumen de: CN120392828A
本发明涉及一种纳米工程化枯草芽孢杆菌及其制备方法与应用，属于生物技术领域。针对现有技术中益生菌递送效率低、肠道致病菌调控不足及ROS清除单一的技术问题，本发明通过构建壳聚糖包裹的枯草芽孢杆菌桥连WO3@PDA纳米颗粒的三元复合体系。本发明将盐酸多巴胺与WO3纳米颗粒自聚合形成WO3@PDA核壳结构；通过pH调控使壳聚糖包覆枯草芽孢杆菌形成BSCS；最后通过静电作用桥连制备BSCS@WO3@PDA复合菌剂。实验表明该制剂可缓解DSS诱导的结肠炎小鼠的炎症症状，并有效实现肠道微生态重编程。本发明为IBD治疗提供了新型纳米‑益生菌协同治疗体系。
Resumen de: WO2024122721A1
The present application relates to a peptide having a cartilage regeneration effect and uses thereof, and provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases, comprising the composition for cartilage regeneration as an active ingredient.
Resumen de: CN120398766A
本公开属于生物医药技术领域，具体涉及阳离子脂质化合物、其脂质纳米颗粒、其组合物及其制备方法与用途。本公开具有如下优点：本公开的阳离子脂质化合物制备的脂质纳米颗粒对核酸具有良好的体内递送效率。
Resumen de: CN120392811A
本发明涉及实验动物病理模型造模技术领域，尤其是涉及一种腺胃炎造模剂及其制备方法和应用。本发明的一种腺胃炎造模剂，包括ZnO‑OTA核芯以及包覆于所述ZnO‑OTA核芯表面的介孔二氧化硅壳层；所述ZnO‑OTA核芯包括氨基化氧化锌纳米颗粒和赭曲霉毒素A。本发明的腺胃炎造模剂中，氨基化氧化锌纳米颗粒与赭曲霉毒素A通过静电吸附作用结合后，采用介孔二氧化硅包覆形成核壳结构；将其应用于肉鸡腺胃炎病理模型的构建，可建立稳定且病理符合率高的腺胃炎模型，所需时间短，造模效果好，在21天内即可建立稳定且病理符合率高的腺胃炎模型。
Resumen de: CN120392699A
本发明之目的就是提供一种吸入载药超声驱动纳米马达的制备方法及其应用，可有效解决吸入载药超声驱动纳米马达的制备，实现在制备治疗IPF药物中的应用问题。包括以下步骤：先制备PLGA‑PFD纳米粒，然后制备PDA‑PLGA‑PFD纳米粒：最后再制备BNN6/PDA‑PLGA‑PFD：即具有超声响应性不对称纳米马达BPPP。本发明产品制备方法科学先进，产品性能好，雾化给药，穿透IPF肺部病理屏障能力强，药物利用率高，疗效好，操作简单方便，有广阔的应用前景，经济和社会效益巨大。
Resumen de: US2025241871A1
Silica nanocarriers hybridized with superparamagnetic iron oxide nanoparticles (“SPIONs”) and curcumin through equilibrium or enforced adsorption technique. Methods for dual delivery of SPIONs and curcumin to a target for diagnosis or therapy, for example, for SPION-based magnetic resonance imaging or for targeted delivery of curcumin to a cell or tissue. The technique can be extend to co-precipitation of mixed metal oxide involving Ni, Mn, Co and Cu oxide. The calcination temperature can be varied from 500-900° C. The nanocombination is functionalized with chitosan, polyacrylic acid, PLGA or another agent to increase its biocompatibility in vivo.
Resumen de: US2025242046A1
Disclosed herein are compositions comprising allogeneic, hypoimmunogenic chimeric antigen receptor (CAR)-targetable biomimetic nanovesicles (BioNVs) and methods of using the same for the treatment, prevention, and/or amelioration of cancer.
Resumen de: US2025242050A1
The present invention can provide a composition for treating gout or a method for treating gout, the composition containing a nano-drug in which a cyclodextrin moiety is conjugated to an amino group of a polymer, wherein a visible or near-infrared fluorophore is further conjugated to a carboxyl group of the polymer or the nano-drug further contains at least one gout therapeutic agent, which forms a complex together with the cyclodextrin moiety.
Resumen de: US2025242048A1
According to one embodiment, a particle-bound lipid nanoparticles includes a biodegradable lipid nanoparticle, a particle bound to an outer surface of the lipid nanoparticle, and an active substance bound to a surface of the particle.
Resumen de: US2025242049A1
It is an object of the present invention to provide a lipid composition capable of delivering a nucleic acid such as RNA to a hematopoietic stem/progenitor cell or mesenchymal stem cells, and a method of delivering a therapeutic agent to a cell using the lipid composition. The present invention provides a lipid composition comprising (A) a therapeutic agent and (B) a lipid nanoparticle conjugated to a targeting molecule, wherein the lipid nanoparticle comprises an ionizable lipid, and the targeting molecule specifically binds to a marker of hematopoietic stem/progenitor cells or mesenchymal stem cells.
Resumen de: US2025242056A1
Provided herein are methods of inserting a nucleic acid encoding a polypeptide of interest into a target genomic locus in a cell or a population of cells in a subject, methods of expressing a polypeptide of interest from a target genomic locus in a cell or a population of cells in a subject, methods of treating an enzyme deficiency in a subject in need thereof, and methods of preventing or reducing the onset of a sign or symptom of an enzyme deficiency in a subject in need thereof. Some methods, such as when a subject has preexisting against an immunogen to be administered, use plasma cell depleting agents or combinations comprising plasma cell depleting agents to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of the nucleic acid construct without overshooting. Other methods, such as when a subject has no preexisting immunity against an immunogen to be administered, use B cell depleting agents (e.g., anti-CD20×CD3 antibody or functional fragment thereof) to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of
Resumen de: US2025242032A1
Provided in the present invention are an aggregate and a preparation method therefor, and an insulin oral preparation. Specifically provided is an aggregate, which is an aggregate formed by means of assembling a chalcogen heterocyclic compound and insulin. The aggregate can be further prepared into an insulin oral preparation. The oral preparation can be used for reducing the blood glucose level of a mammal as part of a diabetes treatment regimen. The chalcogen heterocyclic compound in the insulin oral preparation prepared by means of the method can effectively protect insulin against the three physiological barriers of an oral uptake pathway, is stable in the gastrointestinal tract environment, is subjected to a dynamic chemical exchange reaction with intestinal mucin in intestinal juice and the sulfhydryl groups of proteins inside and outside an epithelial cell membrane by means of the molecular bond of polychalcogen on the surface, and enters the circulation system from the intestinal epithelial cell to achieve the effect of reducing blood glucose. When being orally administered, the insulin oral preparation has high bioavailability, has a good hypoglycemic effect in mammals, and can be used for treating diabetes.
Resumen de: US2025242030A1
Disclosed herein are compositions comprising a polymer and a metabolic inhibitor, as well as a method of using the composition to modulate an immune response. The composition may be produced in the form of a synthetic tissue for provision in a subject. The composition or synthetic tissue may further comprise additional therapeutic agents.
Resumen de: US2025242015A1
The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-E1-A-E2-U-H and H-U-E1-A-E2-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.
Resumen de: US2025242028A1
A metal boride nanoparticle is provided, which has dual functions of tumor diagnosis and therapeutic treatment. A surface of the metal boride nanoparticle is modified with antibodies, bioprobes, or coated with a biological cell membrane, and the antibodies or the bioprobes have a specificity for binding to receptors on specific tumor cells.
Resumen de: US2025241943A1
The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.
Resumen de: US2025241863A1
In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.
Resumen de: US2025241848A1
The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions. Methods generally involve administering nanoparticle compositions (e.g., nanoparticle compositions comprising at least one known therapeutic agent and/or independently active biologically active agent; and/or empty nanoparticle compositions) to a subject in need thereof.
Resumen de: US2025242045A1
Disclosed herein are cell-targeting complexes that are coated on the surface with target specific antibodies for induction of biological stimulus in target cells/tissue/organs. In some embodiments, the cell-targeting complex involves non-nucleated (e.g. platelets, red blood cells (RBC)) or enucleated cells that have been thiolated, streptavidinylated, and then coated with biotinylated antibodies. In some embodiments, the cell-targeting complex involves multilayer alginate hydrogel beads that have been coated with polyanionic proteins using a polycation, which is then thiolated, streptavidinylated, and then coated with biotinylated antibodies.
Resumen de: US2025242059A1
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
Nº publicación: US2025241886A1 31/07/2025
Solicitante:
NANO TARGETING & THERAPY BIOPHARMA INC [TW]
SCINOPHARM TAIWAN LTD [TW]
NANO TARGETING & THERAPY BIOPHARMA INC,
SCINOPHARM TAIWAN LTD
Resumen de: US2025241886A1
The present disclosure relates to a method of preventing or treating brain cancers or brain metastases with mesoporous silica nanoparticles (MSNs) loaded with taxane-based chemotherapeutic drugs, in particular paclitaxel (PTX), cabazitaxel (CTX) or docetaxel (DTX), and the MSNs loaded with PTX, CTX or DTX.
BOPI
Sede Electrónica
